GlassScriptPhysician profile
Alexandra Galati
NPI 1881048759
$2,045.39
in general payments reported to CMS, 2019-2025
18 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $283 · 2023: $625 · 2024: $458 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425 · Education: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.67 |
| Education | $338.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $619.49 | 2024-2025 | Uplizna |
| Abbvie INC. | $508.13 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $196.90 | 2022-2025 | Ultomiris |
| Biogen, INC. | $100.23 | 2023-2025 | Vumerity, Tysabri |
| Pfizer INC. | $99.03 | 2023-2025 | |
| Celgene Corporation | $95.32 | 2022-2025 | Zeposia |
| Genzyme Corporation | $81.77 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $71.71 | 2022-2025 | |
| Horizon Therapeutics Plc | $44.33 | 2023 | Uplizna |
| Eisai INC. | $41.99 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.39 | 2022 | |
| Jazz Pharmaceuticals INC. | $31.38 | 2024 | |
| Tg Therapeutics, INC. | $24.45 | 2023 | |
| Vanda Pharmaceuticals INC. | $21.49 | 2025 | Ponvory |
| Sk Life Science, INC. | $20.21 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $18.00 | 2022 | |
| Genentech USA, INC. | $16.09 | 2023 | Ocrevus |
| Genentech, INC. | $15.48 | 2024 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Galati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.